In wake of Biogen's skirmish with the SEC, pharma giants are changing the way they do quarterly reports

After receiving complaints from the SEC last spring, Biogen changed the way it reports upfront payments to collaborators in its quarterly updates. But it appears Biogen wasn’t the only one who got the message.